Jan. 5 at 12:31 PM
Leerink transferred coverage on
$LRMR at an Outperform rating and a
$12 PT.
$BIIB $LXEO $PTCT
Leerink said:
Bottom Line: We are transferring coverage of LRMR with an Outperform rating and a
$12 PT.
As we approach LRMR's regulatory discussion and open-label study updates in 1Q26 ahead of their plans to submit their BLA filing in 2Q26, there are a lot of questions for this program so we are taking a fresh look at it and the stock's potential reaction to upcoming updates.
After speaking with several MEDACorp specialists and taking many factors into consideration, we believe that the FDA could continue to see a favorable benefit/risk profile for nomlabofusp, especially among patients with severe disease. Thus, we are maintaining an Outperform Rating, although we are lowering our PT to
$12.
